Last month, the stock of coffee shop operator Dutch Bros ( BROS 1.55%) acted as if it had been given a shot of particularly ...

The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...

India’s pharma market expands on volumes, pricing, and chronic-led product momentum India’s pharmaceutical market sustained double-digit growth in March, with anti-diabetic therapies surging on the ...

The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...

As Asia grappled with the impact of the Iran war, a major pharmaceutical milestone quietly made the headlines. On March 20, the patent for semaglutide, the active ingredient in Novo Nordisk’s Ozempic ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the world’s population, significantly lowering the price of a costly medicine that ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...